A US-based KOL provides insights into epidemiology, prescribing habits, key marketed brands, and late-phase pipeline therapies for cystic fibrosis (CF). Treatment strategies and unmet needs are also discussed. Key pipeline assets highlighted include Brensocatib, SION-638. 

This interview was conducted on Oct. 29, 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.